Physician profile
John Joon Lah
NPI 1437221272
$4,244.47
in general payments reported to CMS, 2019-2025
26 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.24 · 2022: $580 · 2023: $1,151 · 2024: $1,165 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.10 | 2022-2025 | |
| Genzyme Corporation | $466.12 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.95 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $339.87 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $327.88 | 2024-2025 | |
| Celgene Corporation | $311.23 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $229.72 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Pharmaceuticals, INC. | $143.16 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $137.37 | 2023 | |
| Exact Sciences Corporation | $124.51 | 2024 | |
| Qol Medical, LLC | $108.83 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $107.98 | 2022-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $104.71 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $88.52 | 2024 | Voquezna |
| Celltrion USA INC. | $52.63 | 2024-2025 | Vegzelma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $48.83 | 2024-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $47.33 | 2022 | |
| Ferring Pharmaceuticals INC. | $44.88 | 2022-2023 | Rebyota |
| Evoke Pharma, INC. | $32.57 | 2022-2023 | Gimoti |
| Lilly USA, LLC | $31.08 | 2024 | Omvoh |
| Alnylam Pharmaceuticals INC. | $28.61 | 2024 | Amvuttra |
| Boston Scientific Corporation | $23.24 | 2021 | |
| Ardelyx, INC. | $20.94 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $20.27 | 2022 | |
| Endogastric Solutions, INC | $16.93 | 2023 | Esophyx |
| Ipsen Biopharmaceuticals, INC | $15.21 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.